A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma to Extend Dosing for up to 48 Weeks Total
Phase of Trial: Phase II
Latest Information Update: 16 May 2017
At a glance
- Drugs CVA 21 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Viralytics
- 07 Jun 2016 Combined results of parent and extension study assessing the dynamics of tumor response (n=70) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 13 Apr 2016 Status changed from active, no longer recruiting to completed.
- 17 Mar 2016 Results from this trial will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2016, according to a Viralytics media release.